Overview
- The study, published June 26, 2026 in the Journal of Experimental Medicine, reports that MUC16-directed CAR T cells killed patient-derived bladder cancer cells in the lab and controlled tumor growth in mouse bladder xenografts.
- Researchers used a computational antigen pipeline to pick MUC16 because it is highly expressed on many bladder tumors yet largely absent from normal tissues, improving target specificity.
- Intravesical administration via catheter worked where intravenous dosing did not: local delivery reduced tumor size, extended survival in mice, and kept CAR T cells from detectable spread outside the bladder.
- Authors say the compartmentalized approach could lower the risk of off-target toxicity that has limited CAR T use in solid tumors and could provide a bladder-sparing option for high-risk or treatment-refractory patients.
- The results are preclinical and meant to de-risk translation; human safety and efficacy have not been tested and the next steps would be early-phase clinical trials and further safety evaluation.